Drug Trial Radar · NCT03912233
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
Last checked: Nov 19, 2026Latest source record: Apr 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Apr 30, 2019
Primary completion
Dec 10, 2019
Study completion Dec 10, 2019
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Apr 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability and efficacy of VX-121 combination therapy in subjects with cystic fibrosis (CF).
Conditions
- Cystic Fibrosis
Interventions
VX-121Drug
Tablets for oral administration.
TEZDrug
TEZ tablet for oral administration.
VX-561Drug
Tablets for oral administration.
TEZ/IVADrug
Fixed-dose combination tablets for oral administration.
IVADrug
Tablets for oral administration.
PlaceboDrug
Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 Through Safety Follow-up (up to Day 75 for Part 1 and up to Day 85 for Part 2)
- Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)Time frame: From Baseline Through Day 29
Locations
26 sites in 5 countries. Site status is shown where the registry gives one.
Keck Medical Center of University of Southern California
Los Angeles, California
Kaiser Permanente
Oakland, California
University of Kentucky.
Lexington, Kentucky
Tulane Medical Center
New Orleans, Louisiana
Boston Children's Hospital
Boston, Massachusetts
University of Minnesota
Minneapolis, Minnesota
Columbia University Medical Center
New York, New York
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina
Nationwide Children's Hospital
Columbus, Ohio
Santiago Reyes, M.D.
Oklahoma City, Oklahoma
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Charite Paediatric Pulmonology Department
Berlin, Germany
Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen
Essen, Germany
Pneumologisches Studienzentrum Muenchen-West
München, Germany
Academic Medical Center
Amsterdam, Netherlands
University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis
Heidelberglaan, Netherlands
UMC St. Radboud
Nijmegen, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
HagaZiekenhuis van den Haag
The Hague, Netherlands
Hospital de Santa Maria
Lisbon, Portugal
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital
London, United Kingdom
Wythenshawe Hospital
Manchester, United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust, The Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom
All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough
Penarth, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.